Novavax, Inc. (NASDAQ:NVAX) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 40,037,310 shares, a decline of 10.2% from the October 13th total of 44,569,528 shares. Currently, 13.8% of the shares of the company are short sold. Based on an average daily volume of 3,915,223 shares, the short-interest ratio is currently 10.2 days.

NVAX has been the topic of several research reports. Cantor Fitzgerald restated a “hold” rating and issued a $2.00 price target on shares of Novavax in a research note on Friday, July 21st. BidaskClub downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Chardan Capital restated a “neutral” rating and issued a $1.50 price target on shares of Novavax in a research note on Thursday, July 27th. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Finally, Ladenburg Thalmann Financial Services upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target on the stock in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $3.12.

Shares of Novavax (NASDAQ NVAX) opened at $1.23 on Friday. Novavax has a 52-week low of $0.73 and a 52-week high of $1.78. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.42 million. During the same quarter in the prior year, the business posted ($0.24) earnings per share. Novavax’s revenue was up 158.5% compared to the same quarter last year. analysts expect that Novavax will post -0.63 earnings per share for the current fiscal year.

In other Novavax news, insider Stanley C. Erck purchased 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the purchase, the insider now owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director James F. Young sold 175,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $1.06, for a total transaction of $185,500.00. The disclosure for this sale can be found here. 4.00% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Profund Advisors LLC lifted its position in Novavax by 0.4% during the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 455 shares during the period. HighTower Advisors LLC lifted its position in Novavax by 3.8% during the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 5,250 shares during the period. Wells Fargo & Company MN lifted its position in Novavax by 2.7% during the first quarter. Wells Fargo & Company MN now owns 343,714 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 8,966 shares during the period. Bank of New York Mellon Corp lifted its position in Novavax by 0.9% during the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock worth $1,555,000 after purchasing an additional 10,347 shares during the period. Finally, American International Group Inc. lifted its position in Novavax by 7.1% during the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 10,965 shares during the period. 38.87% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Novavax, Inc. (NVAX) Sees Large Drop in Short Interest” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/17/novavax-inc-nvax-sees-large-drop-in-short-interest.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.